Literature DB >> 18467911

Bile acid levels are increased in the liver of patients with steatohepatitis.

Márcia M Aranha1, Helena Cortez-Pinto, Adília Costa, Isabel B Moreira da Silva, Maria E Camilo, Miguel Carneiro de Moura, Cecília M P Rodrigues.   

Abstract

BACKGROUND/AIMS: The pathogenesis of steatohepatitis remains largely unknown; however, bile acids may play a role as potential mediators of liver damage. The aim of this study was to characterize bile acid profiles in liver tissue of patients with steatohepatitis.
METHODS: Bile acid composition was determined by gas-liquid chromatography in liver tissue from patients with nonalcoholic steatohepatitis (NASH; n=15), patients with alcoholic steatohepatitis (ASH; n=14), and controls (n=8). Liver biopsies were graded for steatosis, inflammation, and fibrosis.
RESULTS: Bile acids were moderately increased in liver tissue of steatohepatitis patients compared with controls (P<0.05). Deoxycholic, chenodeoxycholic, and cholic acids were elevated by 92, 64, and 43%, respectively, in patients with steatohepatitis (P<0.05). Cholic acid was the prevailing bile acid in NASH patients and in controls. More hydrophobic bile acid species were elevated in ASH patients compared with controls (P<0.05). Significant correlations were found in NASH patients between hepatic chenodeoxycholic acid and fibrosis, and between cholic acid and trihydroxy/dihydroxy bile acids and inflammation (P<0.05). In patients with ASH, cholic acid and trihydroxy/dihydroxy bile acids were correlated with steatosis (P<0.01).
CONCLUSION: This study shows a distinct pattern of bile acids in the liver of patients with steatohepatitis. Further, the association between bile acids and histological liver injury suggests an association of specific bile acids and disease progression, possibly through bile acid-induced liver injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467911     DOI: 10.1097/MEG.0b013e3282f4710a

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  64 in total

1.  Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.

Authors:  Cyrielle Caussy; Cynthia Hsu; Seema Singh; Shirin Bassirian; James Kolar; Claire Faulkner; Nikhil Sinha; Ricki Bettencourt; Naveen Gara; Mark A Valasek; Bernd Schnabl; Lisa Richards; David A Brenner; Alan F Hofmann; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2018-12-02       Impact factor: 8.171

2.  The glucocorticoid receptor agonistic modulators CpdX and CpdX-D3 do not generate the debilitating effects of synthetic glucocorticoids.

Authors:  Guoqiang Hua; Naimah Zein; Laetitia Paulen; Pierre Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-20       Impact factor: 11.205

Review 3.  Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs.

Authors:  Tiara R Ahmad; Rebecca A Haeusler
Journal:  Nat Rev Endocrinol       Date:  2019-10-15       Impact factor: 43.330

Review 4.  The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Mol Aspects Med       Date:  2017-05-05

Review 5.  Microbial Profiles of Cirrhosis in the Human Small Intestine.

Authors:  Tien S Dong; Jonathan P Jacobs; Shehnaz K Hussain
Journal:  Curr Gastroenterol Rep       Date:  2019-08-23

6.  A possible role of chenodeoxycholic acid and glycine-conjugated bile acids in fibrotic steatohepatitis in a dietary rat model.

Authors:  Xiaofang Jia; Yudai Suzuki; Hisao Naito; Husna Yetti; Kazuya Kitamori; Yumi Hayashi; Rina Kaneko; Mina Nomura; Yukio Yamori; Kei Zaitsu; Masashi Kato; Akira Ishii; Tamie Nakajima
Journal:  Dig Dis Sci       Date:  2014-01-22       Impact factor: 3.199

7.  Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids.

Authors:  Aafke W F Janssen; Tom Houben; Saeed Katiraei; Wieneke Dijk; Lily Boutens; Nieke van der Bolt; Zeneng Wang; J Mark Brown; Stanley L Hazen; Stéphane Mandard; Ronit Shiri-Sverdlov; Folkert Kuipers; Ko Willems van Dijk; Jacques Vervoort; Rinke Stienstra; Guido J E J Hooiveld; Sander Kersten
Journal:  J Lipid Res       Date:  2017-05-22       Impact factor: 5.922

8.  Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor α protects against alcoholic liver disease.

Authors:  Heng-Hong Li; John B Tyburski; Yi-Wen Wang; Steve Strawn; Bo-Hyun Moon; Bhaskar V S Kallakury; Frank J Gonzalez; Albert J Fornace
Journal:  Alcohol Clin Exp Res       Date:  2014-04-28       Impact factor: 3.455

9.  Significance of serum adiponectin levels in patients with chronic liver disease.

Authors:  Maria Luisa Balmer; Jeannine Joneli; Alain Schoepfer; Felix Stickel; Wolfgang Thormann; Jean-François Dufour
Journal:  Clin Sci (Lond)       Date:  2010-08-05       Impact factor: 6.124

10.  c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver.

Authors:  Duarte M S Ferreira; Marta B Afonso; Pedro M Rodrigues; André L Simão; Diane M Pereira; Pedro M Borralho; Cecília M P Rodrigues; Rui E Castro
Journal:  Mol Cell Biol       Date:  2014-01-13       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.